Quantcast
Last updated on April 20, 2014 at 21:20 EDT

Latest Actinium Pharmaceuticals Inc. Stories

2013-05-13 08:28:09

Actinium Pharmaceuticals allowed key claims in a cornerstone patent application for treatment of metastatic solid cancers with alpha emitting isotopes NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics for treatment of advanced cancers, announced that the U.S. Patent and Trademark Office (USPTO) has allowed a key patent application in the Company's portfolio....

2013-04-17 16:25:48

Trading Symbol Changed to "ATNM" NEW YORK, April 17, 2013 /PRNewswire/ -- Cactus Ventures, Inc. (OTCBB: CTVN; OTCBB: ATNM), (the "Company") announced today that following the change of the Company's name from Cactus Ventures, Inc. to Actinium Pharmaceuticals, Inc., the Company will change the trading symbol of its common stock on the OTC Bulletin Board to "ATNM." The new name and trading symbol are effective at the open of the market on April 18, 2013. In a Schedule 14C filed...

2013-02-06 16:26:16

NEW YORK, Feb. 6, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTC BB: CTVN) a biopharmaceutical company that develops innovative alpha particle immunotherapeutics, is pleased to announce that Mr. Jack Talley, Actinium's President & CEO will be presenting at the 15(th) Annual BIO CEO & Investor Conference on Monday, February 11(th) at 10:15 AM EST. Mr. Talley will provide an overview of the Company and its corporate activities. The logistics and webcast information are shown...

2013-01-28 08:29:01

NEW YORK, Jan. 28, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, (OTC BB: CTVN), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, reported today that the program of the EMIT: Targeted Radiotherapy conference will feature three presentations devoted to Actinium Pharmaceuticals' clinical programs and technology platform. These presentations will address broadening use of radiolabeled monoclonal antibodies for Hematopoietic Stem Cell...

2013-01-17 12:26:34

NEW YORK, Jan. 17, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a public biopharmaceutical company (OTC BB: CTVN) that develops innovative targeted payload immunotherapeutics, announced that the University of Pennsylvania Health System in Philadelphia, PA has joined the Company's ongoing Phase I/II trial in newly diagnosed elderly patients with acute myeloid leukemia (AML). The trial is designed to establish the safety and efficacy of API's drug Actimab-A in AML patients over...

2013-01-04 08:22:13

NEW YORK, Jan. 4, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: CTVN) today announced that Jack Talley, the company's President and Chief Executive Officer, will be presenting at the Biotech Showcase in San Francisco on Monday, January 7, 2013 at 11:45 AM Pacific Time. The presentation will include an overview of Actinium's clinical stage drug candidates Actimab-A and Iomab-B for treatment of hematological cancers and discussion of its proprietary patented alpha particle...

2013-01-03 16:23:09

NEW YORK, Jan. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. ("Actinium") announced today that it went public via a reverse merger into Cactus Ventures, Inc. (OTCBB: CTVN), a fully reporting public company (the "Company") pursuant to a share exchange agreement dated December 28, 2012. As a result of the share exchange, former shareholders of Actinium became the controlling shareholders of the public Company. On the closing of the share exchange approximately 21% of...

2012-12-26 16:20:55

NEW YORK, Dec. 26, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., a leader in the field of alpha radioimmunotherapy for treatment of advanced cancers, is pleased to announce that it has successfully completed a first closing of $5.1 million in its current round of financing, for which Laidlaw & Company (UK) Ltd. is exclusive placement agent. Funding will be used primarily for further development of Actimab?A, Actinium's lead drug candidate in multicenter Phase I/II trials in Acute...

2012-12-05 08:25:14

NEW YORK, Dec. 5, 2012 /PRNewswire/ -- Actinium Pharmaceuticals reported today that data from two abstracts of studies investigating the company's pipeline hematology product Iomab-B will be presented at the American Society of Hematology's (ASH) 54th Annual Meeting and Exposition in Atlanta (December 8-11, 2012). These abstracts include summaries of data from studies in acute myelogenous leukemia, myelodysplastic syndrome (MDS) and acute lymphocytic leukemia (ALL). Studies presented at this...

2012-11-29 08:28:35

NEW YORK and SIENA, Italy, Nov. 29, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. and Philogen S.p.A. today announced that they have commenced pre-clinical development of Philogen's L19 antibody construct labeled with actinium 225 as a therapeutic payload. The L19 antibody targets newly formed blood vessels that otherwise allow cancers to grow. If successful, this approach will further expand the field of use of alpha emitters. Clinical trials of drug candidates based on alpha...